Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.

doi:10.18632/oncotarget.11943

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.

Oncotarget - 18 Oct 2016

Williams Geoffrey S, Mistry Bina, Guillard Sandrine, Ulrichsen Jane Coates, Sandercock Alan M, Wang Jun, González-Muñoz Andrea, Parmentier Julie, Black Chelsea, Soden Jo, Freeth Jim, Jovanović Jelena, Leyland Rebecca, Al-Lamki Rafia S, Leishman Andrew J, Rust Steven J, Stewart Ross, Jermutus Lutz, Bradley John R, Bedian Vahe, Valge-Archer Viia, Minter Ralph, Wilkinson Robert W

Abstract excerpt

Antibodies that target cell-surface molecules on T cells can enhance anti-tumor immune responses, resulting in sustained immune-mediated control of cancer. We set out to find new cancer immunotherapy targets by phenotypic screening on human regulatory T (Treg) cells and report the discovery of novel activators of tumor necrosis factor receptor 2 (TNFR2) and a potential role for this target in immunotherapy. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Jurkat Cells

Share to Mice, Inbred BALB C

Share to Neoplasms, Experimental

Share to NF-kappa B

Share to Receptors, Tumor Necrosis Factor, Type II

Share to T-Lymphocytes, Regulatory

Source

Open in PubMed Open full text

Identifiers

PMID: 27626702
DOI: 10.18632/oncotarget.11943
PMCID: PMC5356554

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.PMID 27626702Read ↗

Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificitySemantic proximity Read ↗

Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.Semantic proximity Read ↗

Regulatory T cell targeting in cancer: Emerging strategies in immunotherapySemantic proximity Read ↗

The Significance of Tumor Necrosis Factor Receptor Type II in CD8+ Regulatory T Cells and CD8+ Effector T Cells.Semantic proximity Read ↗

Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.Semantic proximity Read ↗

Combination antagonism of TNF superfamily signaling for T cell immunosuppressionSemantic proximity Read ↗

Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamilySemantic proximity Read ↗

The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells.Semantic proximity Read ↗

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancerSemantic proximity Read ↗

Development and Characterization of a Potent Tumor Necrosis Factor-Alpha Blocking AgentSemantic proximity Read ↗

Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunitySemantic proximity Read ↗

Bispecific Antibody Architecture and TNFRSF Target Selection Determine CD8+ T Cell Differentiation and Anti-tumour ImmunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.